Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision changed from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden message.
    Difference
    0.2%
    Check dated 2026-10-11T02:45:32.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed, replacing the study record with an error screen. This makes the trial information at this URL unavailable and leaves only general navigation and footer visible.
    Difference
    19%
    Check dated 2026-09-20T01:20:39.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page adds a 2015 NIH grant/contract note to the study details and updates the document revision from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-29T19:51:46.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.4 to v3.6.5, signaling a small maintenance update to the page. It does not indicate changes to the study results or core information.
    Difference
    0.1%
    Check dated 2026-08-08T19:16:23.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    The page's revision tag updates from v3.6.3 to v3.6.4, reflecting a newer internal version in the footer.
    Difference
    0.1%
    Check dated 2026-07-25T12:55:29.000Z thumbnail image
  8. Check
    101 days ago
    Change Detected
    Summary
    The page shows a revision tag updated from Revision: v3.6.2 to Revision: v3.6.3, indicating a platform update. This change does not modify the study details, eligibility criteria, outcomes, or other content presented on the page.
    Difference
    0.1%
    Check dated 2026-07-04T04:11:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.